Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027

뉴스 본문을 불러오고 있어요.

Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027 | 웨이프 WAPE

Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027

기사 요약

관련 종목

댓글 —